CoChat

Postprogression Survival in Patients With Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy

Hayashi, Hidetoshi, Okamoto, Isamu, Taguri, Masataka, Morita, Satoshi, Nakagawa, Kazuhiko · 2013 · Clinical Lung Cancer
Cited by 35

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2012.09.006

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 19

  1. Breathnach, 2001, Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results, J Clin Oncol, 19, 1734, 10.1200/JCO.2001.19.6.1734 · DOI · Paper page
  2. Carney, 2002, Lung cancer—time to move on from chemotherapy, N Engl J Med, 346, 126, 10.1056/NEJM200201103460211 · DOI · Paper page
  3. Hotta, 2007, Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer, J Thorac Oncol, 2, 96, 10.1097/JTO.0b013e31802bb010 · DOI
  4. Hotta, 2004, Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer, J Clin Oncol, 22, 3852, 10.1200/JCO.2004.02.109 · DOI · Paper page
  5. Wakelee, 2006, Changes in the natural history of nonsmall cell lung cancer (NSCLC)—comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990, Cancer, 106, 2208, 10.1002/cncr.21869 · DOI
  6. Soria, 2010, Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?, Ann Oncol, 21, 2324, 10.1093/annonc/mdq204 · DOI
  7. Hayashi, 2012, Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer, Ann Oncol, 23, 1537, 10.1093/annonc/mdr487 · DOI
  8. Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 · DOI · Paper page
  9. Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4 · DOI · Paper page
  10. Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 · DOI · Paper page
  11. Saad, 2010, Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials, J Clin Oncol, 28, 1958, 10.1200/JCO.2009.25.5414 · DOI · Paper page
  12. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  13. Johnson, 2006, Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis, Lancet Oncol, 7, 741, 10.1016/S1470-2045(06)70800-2 · DOI · Paper page
  14. Sculier, 2008, The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition, J Thorac Oncol, 3, 457, 10.1097/JTO.0b013e31816de2b8 · DOI · Paper page
  15. Brundage, 2002, Prognostic factors in non-small cell lung cancer: a decade of progress, Chest, 122, 1037, 10.1378/chest.122.3.1037 · DOI · Paper page
  16. Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369 · DOI · Paper page
  17. Ramlau, 2006, Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer, J Clin Oncol, 24, 2800, 10.1200/JCO.2005.03.6491 · DOI
  18. Herbst, 2010, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial, Lancet Oncol, 11, 619, 10.1016/S1470-2045(10)70132-7 · DOI · Paper page
  19. Takeda, 2009, Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104), Ann Oncol, 20, 835, 10.1093/annonc/mdn705 · DOI

Cited by

Metadata

Authors
Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2013-05
Volume
14
Issue
3
Pages
261-266
ISSN
1525-7304
Cited by
35
References
4
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.